Context Therapeutics 未能实现季度收益，股价下跌，但维持“买入”评级。 Context Therapeutics missed quarterly earnings, dropping its stock, but maintained a "buy" rating.

Context Therapeutics 报告称，季度亏损每股 0.22 美元，低于分析师的预期 0.11 美元，导致其股价下跌 0.14 美元至 1.95 美元。 Context Therapeutics reported a quarterly loss of $0.22 per share, missing analysts' estimates by $0.11, leading to a $0.14 drop in its stock price to $1.95. 尽管收入不足, HC Wainwright 仍维持“买入”评级, 标价为6美元。 Despite the earnings miss, HC Wainwright maintained a "buy" rating with a $6.00 price target. 生物制药公司的重点是开发固体肿瘤的治疗方法,包括其主要候选者CTIM-76。 The biopharmaceutical company focuses on developing treatments for solid tumors, including its lead candidate CTIM-76.